<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18368" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Bleeding Time</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Russeau</surname>
            <given-names>Andrew P.</given-names>
          </name>
          <aff>Advocate Illinois Masonic</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vall</surname>
            <given-names>Hacen</given-names>
          </name>
          <aff>Ege University Faculty of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Manna </surname>
            <given-names>Biagio</given-names>
          </name>
          <aff>RWJUH/Barnabas Health System</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Andrew Russeau declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hacen Vall declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Biagio Manna declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18368.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Bleeding time is a clinical laboratory test performed to evaluate platelet function. It involves the creation of a standardized incision and timing the cessation of bleeding. The historical indications were the pre-operative assessment of patients taking aspirin or NSAIDs and screening for von-Willebrand disease. Unfortunately, it is insensitive and lacks reproducibility.<xref ref-type="bibr" rid="article-18368.r1">[1]</xref> Platelet function assay (i.e PFA 100) has largely replaced bleeding time. Despite standardization of methods, the sensitivity and specificity of the bleeding time for platelet-mediated coagulopathy is low.</p>
        <p>Many hospitals and health systems have removed the test without any demonstrated harm. In most cases, a thorough history and physical is the only workup needed for the pre-operative assessment of bleeding risk. When the clinical effectiveness of platelet aggregation is desired, a modern platelet function assay can provide the necessary&#x000a0;information. This is being increasingly utilized in intracranial hemorrhage on various antiplatelet agents prior to pooled platelet transfusion.</p>
      </sec>
      <sec id="article-18368.s2" sec-type="Specimen Collection">
        <title>Specimen Collection</title>
        <p>While measuring the bleeding time requires trained personnel, no gross specimen collection is necessary. Modern alternative platelet function analyzers require a small aliquot of peripheral blood.&#x000a0;Technicians utilize standardized instruments to perform and interpret the test. &#x000a0;</p>
      </sec>
      <sec id="article-18368.s3" sec-type="Procedures">
        <title>Procedures</title>
        <p>This test is performed via two primary methods based on the length and location of the incision.&#x000a0;&#x000a0;</p>
        <p>The IVY method is the most common. The patient&#x02019;s arm is positioned at the level of the heart, and a blood pressure cuff inflated to 40 mmHg. After cleansing with alcohol, a standardized device is utilized to make a 10mm long and 1mm deep incision on the volar forearm. Using a timer the blood is blotted twice a minute. The time stops when there is no further bleeding after blotting.&#x000a0;&#x000a0;</p>
        <p>The Duke method involves a stab incision in the patient&#x02019;s cleaned finger or earlobe with a lancet. Otherwise, the methodology is the same.&#x000a0;&#x000a0;</p>
        <p>The IVY method is more accurate but has an increased scarring risk. The Duke method is less accurate and carries a higher hematoma rate.&#x000a0;&#x000a0;</p>
        <p>Either method carries the risks of infection and bleeding. In addition, the discomfort is not insignificant.&#x000a0;Different normal ranges exist for each method further confounding the interpretation of results by lay clinicians.</p>
      </sec>
      <sec id="article-18368.s4" sec-type="Indications">
        <title>Indications</title>
        <p>The measurement of bleeding time is mostly of historical value in the screening of qualitative platelet abnormalities. It was used to screen for bleeding disorders and quantify platelet function in patients taking aspirin or non-steroidal anti-inflammatory medications. The American College of Clinical Pathologists position statement identifies a carefully conducted clinical history that includes family and previous dental, obstetric, surgical, traumatic injury, transfusion, and drug histories as the best predictor of bleeding risk.<xref ref-type="bibr" rid="article-18368.r2">[2]</xref> As most hospitals and laboratories have removed this exam from their offerings, it has fallen out of regular use. Most current uses are likely grounded in physician preference rather than clinical research.</p>
      </sec>
      <sec id="article-18368.s5" sec-type="Potential Diagnosis">
        <title>Potential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Thrombocytopenia
<list list-type="bullet"><list-item><p>Decreased platelet count impairs primary hemostasis. Sepsis, drug reactions, hematologic malignancies, autoimmune conditions, and vitamin deficiencies are among the non-inherited causes. Spontaneous bleeding is not generally&#x000a0;a problem seen until counts fall beneath 30,000.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Von Willebrand Disease (vWD)
<list list-type="bullet"><list-item><p>Von Willebrand disease is an inherited deficiency in the quantity or function of the platelet aggregation protein Von Willebrand factor. Rather than bleeding time,&#x000a0; modern workup includes complete blood count, factor VIII levels, ristocetin cofactor activity, and GP-Ib binding assay.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Disseminated Intravascular Coagulation (DIC)
<list list-type="bullet"><list-item><p>DIC is a symptom of other severe disease processes like sepsis, burns, trauma, pregnancy, and malignancy. The coagulopathy is consumptive from the formation of blood clots throughout the peripheral vasculature. Thrombocytopenia with low fibrinogen and a high INR are the classic laboratory abnormalities.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Glanzmann&#x02019;s&#x000a0;
<list list-type="bullet"><list-item><p>Glanzmann's thrombasthenia is an autosomal recessive inherited defect in the fibrinogen binding receptor glycoprotein IIb/IIIa.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Bernard-Soulier Disease
<list list-type="bullet"><list-item><p>Bernard-Soulier Syndrome is a rare autosomal recessive genetic defect in glycoprotein Ib causing giant platelets with perceived thrombocytopenia. Platelet transfusion is the treatment of choice.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Platelet Function Inhibiting Medications (aspirin, clopidogrel, ticagrelor, etc.)
<list list-type="bullet"><list-item><p>Aspirin and other novel antiplatelet agents inhibit platelet aggregation and secretion overall inhibiting their function.</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18368.s6" sec-type="Normal and Critical Findings">
        <title>Normal and Critical Findings</title>
        <p>Normal bleeding time:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Duke&#x000a0;&#x02013;&#x000a0;Less than 3 minutes&#x000a0;</p>
          </list-item>
          <list-item>
            <p>IVY&#x000a0;&#x02013;&#x000a0;Less than 8 minutes&#x000a0;</p>
          </list-item>
        </list>
        <p>Times greater than 5 minutes in the Duke method and 10 minutes in the IVY method are concerning for coagulopathy. Abnormalities would require further evaluation with a focus on the coagulation pathway of interest.</p>
      </sec>
      <sec id="article-18368.s7" sec-type="Interfering Factors">
        <title>Interfering Factors</title>
        <p>Anything that alters platelet function can interfere with the bleeding time. Some examples include aspirin, thrombocytopenia, and uremia. Additional factors include the test procedure and subjective observation by the performing technician. As with all subjective tests, this one is at risk of human error.</p>
      </sec>
      <sec id="article-18368.s8" sec-type="Complications">
        <title>Complications</title>
        <p>Both methods carry a risk of local scarring due to the incision, but this is worse in the IVY technique. Local pain, infection, hematoma, and aberrant results are other potential complications.&#x000a0;The risk of misdiagnosis due to the poor sensitivity and specificity of bleeding time is an often unaccounted complication.</p>
      </sec>
      <sec id="article-18368.s9" sec-type="Patient Safety and Education">
        <title>Patient Safety and Education</title>
        <p>The University of Utah Health Sciences Center undertook a retrospective review of bleeding complications in kidney biopsy five months before and after discontinuation of the bleeding time test. There were no statistically significant differences in post-procedural complications, DDAVP administration, or transfusions between the two groups. Additionally, the clinicians surveyed did not alter their workup and treatment of these patients.<xref ref-type="bibr" rid="article-18368.r3">[3]</xref>&#x000a0;This data supports the&#x000a0;removal of bleeding time from the workup of presurgical patients. Although the test is safe, its use continues to come under scrutiny due to low sensitivity and specificity. If your doctor requests this test, inquire whether a platelet function assay would be more appropriate. Consultation with a hematologist is the proper recommendation if the clinical picture is unclear.</p>
      </sec>
      <sec id="article-18368.s10" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Clinicians have sought a global test to assess the adequacy of primary hemostasis. While the bleeding time seems the logical fit, it has proven a poor predictor of clinical bleeding. Its diagnostic sensitivity and specificity are also disappointingly low. &#x0201c;The bleeding time is affected by a large number of diseases, drugs, physiologic factors, test conditions, and therapeutic actions, not all of them platelet-related.&#x0201d;<xref ref-type="bibr" rid="article-18368.r4">[4]</xref> In May 2011 a double-blinded randomized control trial demonstrated that several points of care platelet function analyzers were equal or superior to bleeding time in the diagnosis of aspirin and clopidogrel mediated coagulopathy.<xref ref-type="bibr" rid="article-18368.r5">[5]</xref> With the adoption of modern platelet function analyzers, this test has largely been abandoned.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-18368.s11">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18368&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18368">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18368/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18368">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18368.s12">
        <title>References</title>
        <ref id="article-18368.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kruse-Jarres</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Singleton</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Leissinger</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Identification and basic management of bleeding disorders in adults.</article-title>
            <source>J Am Board Fam Med</source>
            <year>2014</year>
            <season>Jul-Aug</season>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>549</fpage>
            <page-range>549-64</page-range>
            <pub-id pub-id-type="pmid">25002009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18368.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peterson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Arkin</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Bovill</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Fairweather</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Rock</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Triplett</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Brandt</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article.</article-title>
            <source>Arch Surg</source>
            <year>1998</year>
            <month>Feb</month>
            <volume>133</volume>
            <issue>2</issue>
            <fpage>134</fpage>
            <page-range>134-9</page-range>
            <pub-id pub-id-type="pmid">9484723</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18368.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lehman</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Blaylock</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Rodgers</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Discontinuation of the bleeding time test without detectable adverse clinical impact.</article-title>
            <source>Clin Chem</source>
            <year>2001</year>
            <volume>47</volume>
            <issue>7</issue>
            <fpage>1204</fpage>
            <page-range>1204-11</page-range>
            <pub-id pub-id-type="pmid">11427450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18368.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodgers</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A critical reappraisal of the bleeding time.</article-title>
            <source>Semin Thromb Hemost</source>
            <year>1990</year>
            <month>Jan</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-20</page-range>
            <pub-id pub-id-type="pmid">2406907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18368.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Maridakis</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>O'neill</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Beals</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Radziszewski</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>de Lepeleire</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Van Dyck</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Depr&#x000e9;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bolognese</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>de Hoon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jacquemin</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A randomized clinical trial comparing point-of-care platelet function assays and bleeding time in healthy subjects treated with aspirin or clopidogrel.</article-title>
            <source>Platelets</source>
            <year>2012</year>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>249</fpage>
            <page-range>249-58</page-range>
            <pub-id pub-id-type="pmid">21919555</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
